BEST PRACTICES: Overcoming Patient Challenges Associated With Basal-Bolus Insulin Therapy in Type 2 Diabetes

A supplement to Clinical Endocrinology News. This supplement was sponsored by Valeritas, Inc.

®  1

Important Risk Information:
If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with the V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. The V-Go should be removed before any magnetic resonance imaging (MRI) testing.

Reference: 1. Brunton S, Carmichael B, Funnell, Lorber D, Rakel R, Rubin R. Type 2 diabetes: the role of insulin. J Fam Pract. 2005;54(5):445-452.

Best Practices in Overcoming Patient Challenges Associated With BasalBolus Insulin Therapy in Type 2 Diabetes is a copyrighted production of Frontline Medical Communications © 2013.

This video is sponsored by

To learn more about the V-Go contact Valeritas Customer Care at 1-866-881-1209 or visit www.go-vgo.com.

This email has been sent to you from IMNG Medical Media, a Frontline Medical Communications company, 7 Century Drive, Suite 302, Parsippany, NJ 070544609 United States. If you prefer not to receive future marketing emails from IMNG Medical Media, please click link below to unsubscribe. We will promptly remove you from our email list.

ART-499 Rev:A 04/2013 © 2013 Valeritas, Inc.

A supplement to Clinical Endocrinology News. This supplement was sponsored by Valeritas, Inc.

®  1

Important Risk Information:
If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with the V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. The V-Go should be removed before any magnetic resonance imaging (MRI) testing.

Reference: 1. Brunton S, Carmichael B, Funnell, Lorber D, Rakel R, Rubin R. Type 2 diabetes: the role of insulin. J Fam Pract. 2005;54(5):445-452.

Best Practices in Overcoming Patient Challenges Associated With BasalBolus Insulin Therapy in Type 2 Diabetes is a copyrighted production of Frontline Medical Communications © 2013.

This video is sponsored by

To learn more about the V-Go contact Valeritas Customer Care at 1-866-881-1209 or visit www.go-vgo.com.

This email has been sent to you from IMNG Medical Media, a Frontline Medical Communications company, 7 Century Drive, Suite 302, Parsippany, NJ 070544609 United States. If you prefer not to receive future marketing emails from IMNG Medical Media, please click link below to unsubscribe. We will promptly remove you from our email list.

ART-499 Rev:A 04/2013 © 2013 Valeritas, Inc.

A supplement to Clinical Endocrinology News. This supplement was sponsored by Valeritas, Inc.

®  1

Important Risk Information:
If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with the V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. The V-Go should be removed before any magnetic resonance imaging (MRI) testing.

Reference: 1. Brunton S, Carmichael B, Funnell, Lorber D, Rakel R, Rubin R. Type 2 diabetes: the role of insulin. J Fam Pract. 2005;54(5):445-452.

Best Practices in Overcoming Patient Challenges Associated With BasalBolus Insulin Therapy in Type 2 Diabetes is a copyrighted production of Frontline Medical Communications © 2013.

This video is sponsored by

To learn more about the V-Go contact Valeritas Customer Care at 1-866-881-1209 or visit www.go-vgo.com.

This email has been sent to you from IMNG Medical Media, a Frontline Medical Communications company, 7 Century Drive, Suite 302, Parsippany, NJ 070544609 United States. If you prefer not to receive future marketing emails from IMNG Medical Media, please click link below to unsubscribe. We will promptly remove you from our email list.

ART-499 Rev:A 04/2013 © 2013 Valeritas, Inc.